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The recent development of powerful “omics” technologies (genomics, transcriptomics,
proteomics, metabolomics, and lipidomics) has opened new avenues in nutritional
sciences toward precision nutrition, which is a genotype-directed nutrition that takes into
account the differential responses to nutritional interventions based on gene variation
(nutrigenetics) and the effect of nutrients on gene expression (nutrigenomics). Current
evidence demonstrates that up to one third of the deaths caused by cancer could be
prevented by acting on key risk factors, with diet being one of the most important risk
factors due to its association with obesity. Additional factors such as composition of
gut microbiome, the immune system, and the nutritional status will have an impact on
the final outcome. Nutrient components and bioactive compounds from natural sources
can have an impact on cancer progression or even the risk of cancer development by
regulating gene expression and/or associated risk factors such as obesity and chronic
inflammation. Nowadays, among the different methods to produce natural extracts, the
green technology of supercritical fluid extraction (SFE) is quite popular, with a special
interest on the use of supercritical CO2 for the extraction of compounds with low
polarity. The success of nutritional interventions based on the use of nutraceuticals
requires several steps: (i) in vitro and preclinical demonstration of their antitumoral
effects; (ii) knowledge of their mechanism of action and molecular targets, which will
allow for identification of the specific subgroups of patients who will benefit from
them; (iii) the study of genetic variants associated with the differential responses; and
(iv) innovative approaches of formulations to improve the in vivo bioavailability of the
bioactive ingredients. Herein, we investigate the antitumoral properties and mechanism
of action of a supercritical CO2 extract from Calendula officinalis, commonly known as
marigold (marigold SFE) in the context of pancreatic cancer. Mechanistically, marigold
SFE induces the expression of BMP8B, which leads to an energetic catastrophe
ending up with autophagy-induced cell death (AICD). As metabolic reprogramming is
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a well-recognized hallmark of cancer, the direct impact of marigold SFE on pancreatic
cancer cell metabolism encourages further research of its potential as a coadjuvant
in pancreatic cancer therapy. Finally, we discuss innovative formulation approaches to
augment the clinical therapeutic potential of marigold SFE in nutritional interventions.
Keywords: precision nutrition, supercritical extract, marigold, cell bioenergetics, cancer
INTRODUCTION
In the last years, there is great concern about the increase
of chronic diseases related to metabolism including metabolic
syndrome, cardiovascular disease, insulin resistance, obesity, and
cancer. Importantly, it has been estimated that up to one third
of cancer deaths could be prevented by modifying key risk
factors, such as diet and exercise, due to their association with
obesity (Parkin et al., 2011; Brown et al., 2018). Numerous
epidemiological studies have shown that obesity increases the risk
of developing different types of cancer (Lauby-Secretan et al.,
2016), and accumulating evidence demonstrates that the overall
metabolic state of an individual may contribute to the molecular
alterations during the carcinogenic process. A key event during
tumorigenesis is the reprogramming of the cancer energetic
metabolism (Hanahan and Weinberg, 2011), and obesity-
associated alterations (hormones, growth factors, cytokines, and
other inflammatory molecules) may promote protumoral signals
in pre- or neoplastic cells by interacting through their receptors
and/or downstream intracellular signaling pathways (Gunter
et al., 2015; Renehan et al., 2015; Murphy et al., 2018).
The recent development of powerful “omics” technologies
[genomics, transcriptomics (Chen et al., 2007), proteomics (Sun
et al., 2018), methylomics (Gaunt et al., 2016; Richmond et al.,
2016), metabolomics (Shin et al., 2014; Würtz et al., 2014),
lipidomics, microbiomics (Wang et al., 2018)] has opened
new avenues in nutritional sciences toward precision nutrition.
In the context of cancer, together with chemotherapy and/or
radiotherapy used in the clinics, precision nutrition can help
by means of the use of natural extracts, bioactive compounds,
and nutritional recommendations to modulate gene expression
and/or cancer-associated risk factors such as obesity, which
will have an impact on the risk of developing this disease or
its progression.
The success of such nutritional interventions requires
several steps: (i) in vitro and preclinical demonstration of
the antitumoral effects of selected extracts and/or bioactive
compounds; (ii) the knowledge of their mechanism of action
and molecular targets, which will identify the specific subgroups
of patients who will benefit from them; (iii) the study of
genetic variants associated with the differential responses to the
intervention; and (iv) innovative approaches of new formulations
to improve the in vivo bioavailability of the bioactive ingredients.
Additional factors such as the gut microbiome composition,
the immune system, and the nutritional status will refine the
final outcome.
The use of phytochemicals and dietary-derived compounds
in cancer prevention and/or treatment is well-demonstrated
(Mouhid et al., 2017; Pan et al., 2017; Kumar et al., 2018; Imran
et al., 2019; Tarasiuk and Fichna, 2019), such as taxol and
camptothecin, which are extensively used in the clinics (Denda
et al., 2019; Sanoff et al., 2019; Ulusakarya et al., 2019). Metabolic
reprogramming in cancer not only supports the proliferation
but also promotes malignancy and dissemination of cancer cells.
In this regard, the exacerbated glucose uptake (Warburg effect)
of proliferating cancer cells (Hanahan and Weinberg, 2011;
Derle et al., 2018), the increased glutaminolysis supporting the
proliferation and redox homeostasis (Li and Le, 2018; Bott et al.,
2019), or lipid metabolism alterations associated with cancer
dissemination (Currie et al., 2013; Luo et al., 2018; Munir et al.,
2019) are well-documented.
One of the most popular sources of bioactive compounds
are vegetables and plants. Phytochemicals exert important
biological activities, such as anti-inflammatory, antihypertensive,
antioxidant, anticarcinogenic, antidiabetic, or antiobesity.
For these reasons, current efforts are done toward the
development of innovative methodologies to obtain bioactive
compounds and/or natural extracts. Within the most promising
methods, there is the green technology of supercritical fluids,
with special use of supercritical CO2 in the extraction of
compounds with low polarity. This technology can be assisted
by distinct co-solvents in order to augment the performance of
the extraction.
Herein, we have investigated the antitumoral properties
and mechanism of action of a supercritical CO2 extract from
Calendula officinalis, commonly known as marigold, in the
context of pancreatic cancer.
Pancreatic cancer leads to the second position of deaths
related to cancer worldwide. This cancer has poor prognosis, and
the overall 5-year survival rate is <5%. Several risk factors in
pancreatic cancer are obesity and chronic pancreatitis, tobacco
smoking, alcohol intake, or diets with high intake of red meat
(Ilic and Ilic, 2016; Gordon-Dseagu et al., 2017; Michaud, 2017;).
Pancreatic cancer is often diagnosed at metastatic late stages
due to the absence of indicators of illness. Although surgery
remains the main beneficial treatment followed by chemotherapy
(gemcitabine, 5-fluorouracil, irinotecan, and/or oxaliplatin) and
radiation, as indicated previous, the patient’s survival is limited.
Therefore, there is an urgent necessity to investigate on
effective therapeutic strategies to improve patients’ survival.
Recently, we have described the antitumoral properties of
marigold supercritical fluid extract (marigold SFE) (Martin et al.,
2016; García-Risco et al., 2017), in pancreatic cancer cell lines
(Mouhid et al., 2018). Marigold SFE diminished the cell viability
of pancreatic cancer cells in a dose-dependent manner, induced
apoptotic cell death, increased the percentage of necrotic cells,
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 2 January 2020 | Volume 7 | Article 455
Gómez de Cedrón et al. Marigold-SFE as Adjuvant in Pancreatic-Cancer
inhibited the anchorage-independent cell growth, and synergized
with the chemotherapeutic drug 5-fluorouracil (5-Fu), used
in clinics.
Herein, we investigate the impact of marigold SFE on
pancreatic cancer metabolism. By means of the use of the latest
technology in the field of the analysis of cell bioenergetics, we
demonstrate that marigold SFE targets the two main sources
for energy production, mitochondrial oxidative respiration,
and aerobic glycolysis. Marigold SFE leads to an energetic
catastrophe, which ends up with autophagy-induced cell death
(AICD). By means of gene expression microarray analysis, we
identify the bone morphogenetic protein-8B (BMP8B) as a
validated molecular target of marigold SFE.
The direct impact of marigold SFE on pancreatic cancer
cell metabolism encourages further research of its potential
as a complementary adjuvant in pancreatic cancer therapy.
Finally, we discuss innovative formulation approaches to
augment the clinical therapeutic potential of marigold SFE in
nutritional interventions.
Figure 1 summarizes the study workflow and challenges in the
field of precision nutrition and nutraceuticals to be applied in
cancer and other chronic diseases.
MATERIALS AND METHODS
Marigold Supercritical Extract
Marigold SFE was obtained by CO2 supercritical fluid extraction
(Thar Technology, model SF2000) in previously optimized
process conditions (Martin et al., 2016). Briefly, a CO2 flux of
70 g/min at 140 bar and 40◦C for 180min was applied to 400 g
of dried and grounded marigold in a 2-L cylinder. The resulting
extract was collected with absolute ethanol, and the dissolvent
was removed bymeans of rotary evaporation at 30◦C. The extract
chemical composition has been described in a preceding article
(García-Risco et al., 2017).
Cell Culture
Pancreatic cancer cells, MiaPaCa-2 and Panc-1, were obtained
from American Type Culture Collection (Manassas, VA) and
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS; LONZA
Iberica, S.A.) in an incubator with 95% humidity and 5% CO2.
Extracellular Flux Analysis of the
Acidification Rate and the Oxygen
Consumption Rate
Mitochondrial oxidative respiration (Cell MitoStress Test) and
aerobic glycolysis (Cell GlycoStress Test) were monitored
with the XFe96 Cell Bionalyzer (Seahorse Biosciences,
XFe96). Optimal cell density and drugs tritation were
previously determined.
The dependency of the cells for aerobic glycolysis and
oxidative phosphorylation was monitored after the injection of
several modulators of both bioenergetic pathways.
Prior to the experiments, cells were pretreated with different
doses of marigold SFE for 48 h. Non-treated cells were kept
as controls.
For GlycoStress assay, 20,000 cells were plated in an XFe-
96 well-plate and kept for 6 h in DMEM 10% FBS to allow
the cells to attach. Then, the culture medium was changed to
0.2mM glutamine XFe DMEM (5mM Hepes) to starve the cells
for 1 h. First basal extracellular acidification rate (ECAR) was
measured (1–3 measurements). Glucose (10mM) was injected
(4–6 measurements) to the cells to determine glycolysis (this
FIGURE 1 | Precision nutrition and nutraceuticals.
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is the increased ECAR from basal starved situation after
glucose addition). This indicates the capacity of the cells to
use glucose. Next, maximal glycolytic capacity was monitored
(7–9 measurements) after the injection of oligomycin, which
inhibits the ATP production from the oxidative mitochondrial
respiration. Finally, a third injection with 50mM DG was
done to specifically shut down aerobic glycolysis (10 to
12 measurements).
For MitoStress assay, 40,000 cells were plated in an XFe-
96 well-plate, and cells were kept for 6 h in DMEM 10%
FBS to allow the cells to attach. Then, the medium was
changed to 10mM glucose, 2mM glutamine, and 1mM pyruvate
XFe DMEM (5mM Hepes), and cells were incubated for
1 h at 37◦C without CO2. Three different modulators of
the mitochondrial respiration were sequentially injected. After
basal oxygen consumption rate (OCR) determination (1–3
measurements), oligomycin (1µM), which inhibits ATPase, was
injected to determine the amount of oxygen dedicated to ATP
production by mitochondria (3–6 measurements). To determine
the maximal respiration rate or spare respiratory capacity,
FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone)
was injected (0.4µM) to free the gradient of H+ from the
mitochondrial intermembrane space (7–9 measurements) and
thus to activate maximal respiration. Finally, antimycin A
and rotenone (0.5µM) were added to completely inhibit the
mitochondrial respiration (10–12 measurements).
Measurement of Cellular ATP Content
For the quantification of the ATP content, the ATP-based assay
CellTiter-Glo, Luminescent Cell Viability kit was used (Promega,
Madison, WI, USA; Cat. #G7571) following the manufacturer’s
recommendations. Briefly, MiaPaca-2 cells were first pretreated
(48 h) with marigold SFE at ½ × IC50, 1 × IC50, and 2 ×
IC50, with IC50 being equal to 39.8 (± 4.6) µg/ml as previously
described (Mouhid et al., 2018). Non-treated cells were kept
as controls. A total of 10,000 MiaPaca-2 cells were plated in
96-well-clear bottom black polystyrene plates.
Western Blot
After 48 h of treatment with marigold SFE, MiaPaca-2 or Panc-1
pancreatic cancer cells were washed and detached using trypsin.
The RIPA buffer with protease and phosphatase inhibitors was
used to lyse the cells. After centrifugation (12,000 g) for 10min
at 4◦C, supernatants were recovered. Proteins were denatured
and loaded into a 4–15% Mini-Protean TGX Precast Protein Gel
(BioRad) for electrophoretic separation, and transferred onto a
nitrocellulose membrane. Membranes were blocked using 5%
no-fat dry milk in TBS 0.05% Tween-20. Primary antibodies
were incubated overnight at 4◦C, and secondary antibodies
were incubated for 1 h. β-Actin or Ponceau staining was
used as the loading control. The primary antibodies used were
rabbit polyclonal anti-LC3 (PM036, 1:1,000 dilution, MBL),
rabbit monoclonal anti-phospho-AMPKα (T172) (40H9, 1:1,000
dilution, Cell Signaling), and rabbit monoclonal anti-AMPKα
antibody (23A3, 1:1,000 dilution, Cell Signaling). For loading
controls, β-actin (Sigma-Aldrich) or Ponceau staining was used.
Signals were visualized using ECL plus (GE Healthcare, Little
Chalfont, UK).
Immunofluorescence
MiaPaca-2 cells were spread in M24 well-plates on top of glass
coverslips for o/n. Then cells were treated with different doses of
marigold SFE (1 × IC50, 2 × IC50) for 48 h. Non-treated cells
were kept as the control. Cells were fixed in 4% PFA/PBS for
10min at RT. Then cells were permeabilized with 100µg/ml of
digitonin for 20min at RT. After washing with PBS, anti-LC3
antibody (1:1,000) was added and incubated for 1 h at RT. After
washing, 1:500 Alexa Fluor 488 Goat Anti-rabbit IgG (Invitrogen,
A11008) was incubated for 30min at RT. DAPI was incubated for
5min at RT. Positive controls were incubated for 6 h in Hank’s
solution at 37◦C. E64d and pepstatin A treatments were done at
10µM and 10µg/ml, respectively.
Quantitative Real-Time Polymerase Chain
Reaction
MiaPaca-2 and Panc-1 cells (0.35 × 106 cells) were treated with
marigold SFE for 48 h at different doses: ½ IC50, 1 × IC50, 2
× IC50, with IC50 values being equal to 39.8µg/ml (± 4.6) and
43.2µg/ml (±7.9), respectively, for MiaPaca-2 and Panc-1, as
previously described (Mouhid et al., 2018). Non-treated cells
were kept as controls.
Total RNA was extracted with Tri Reagent (Sigma). One
microgram of RNA was reverse-transcribed with the High
Capacity RNA-to-cDNAMaster Mix system (Life Technologies).
Quantitative polymerase chain reaction (qPCR) was performed
in the 7900HT Real-Time PCR System (Life Technologies) using
the VeriQuest SYBR Green qPCR Master Mix (Affymetrix, Santa
Clara, CA, USA), and Taqman probes were used: Hs01629120_s1,
Hs01029413_m1, Hs00245183_m1, and Hs99999901_s1 for
BMP8B, TFAP2A, ZFP36L1, and 18S, respectively; or oligos
in the case of the epithelial-to-mesenchymal transition (EMT),
stemness and endoplasmic reticulum (ER) stress markers
(Table S1 displays the list and sequences of the primers used).
The 2−11Ct method was applied to calculate the relative gene
expression (Livak and Schmittgen, 2001).
Microarray Gene Expression Assay
MiaPaca-2 cells were plated (2 × 106) in p100 plates and 12 h
later were treated for 48 h with 30 and 70µg/ml of marigold SFE.
Non-treated cells were kept as controls. Total RNA was isolated
with the RNeasy Mini Kit (Qiagen Iberica). The microarray
gene expression analysis between control and treated cells was
performed by the Genomic Service of the National Center
of Biotechnology (CNB-Madrid, Spain). After RNA integrity
validation, RNAs were reverse transcribed and fluorescently
tagged with the one-color Low Input Quick Amp Labeling
Kit (Agilent Technologies). The microarray gene expression
platform used was the Agilent Sure Print G3 Human 8 × 60K
(Whole Human Genome Microarray Kit).
BMP8B Depletion With si-RNA-Pools
Cells (0.25 × 106) were plated in six-well-plates with si-
RNA pools (siTOOLs Biotech GmbH, Planegg, Germany)
against the human BMP8B mRNA to transiently deplete the
expression of BMP8B. Lipofectamine RNAimax was used (Life
Technologies, Darmstadt, Germany) to transfect MiaPaca-2 and
Panc-1 pancreatic cancer cells for 4 to 6 h. After that, cells were
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treated with the indicated doses of marigold SFE for 48 h. Cells
transfected with a negative control siPOOL against sequences not
found in human were kept as controls. The functional role of
BMP8B depletion on cell bioenergetics was further analyzed.
Invasion Assays
Matrigel-coated chambers (BD Biosciences Madrid, Spain) were
used for invasion assays. Images were obtained with the
Olympus CKX41 microscope. The analysis was done with the
GETIT software.
Statistical Analysis
Microarray gene expression data were analyzed with FIESTA
software (version 1.0) Statistical analyses were performed using
Limma (Smyth, 2005). A P < 0.05 was set to establish the
limit of significance and a change of two-fold or higher fold
to consider upregulation or repression of the genes. One-way
analysis of variance (ANOVA; Bonferroni post-hoc test) was used
to determine qPCR differences between gene expression and
invasion through Matrigel-coated chambers. ∗P < 0.05, ∗∗P <
0.01, and ∗∗∗P< 0.005 indicate significant differences. GraphPad
Prim 8.0.1 statistical software was used for all statistical analyses.
RESULTS
Marigold SFE Diminishes the Cell
Bioenergetics of Pancreatic Cancer Cells
In the last years, there is an increased interest on targeting the
altered cancer metabolism. In a previous work, we have described
the antitumoral effects of marigold SFE in pancreatic cancer cell
lines (marigold SFE inhibited cell viability, induced apoptosis,
and augmented the percentage of necrotic cells) (Mouhid et al.,
2018). For this reason, herein, we aimed to investigate if marigold
SFE could target cancer cell metabolism, andmore specifically the
energetic metabolism (glycolysis and mitochondrial respiration)
of pancreatic cancer cells.
Marigold SFE Diminishes the Mitochondrial
Respiration of Pancreatic Cancer Cells
First, we investigated the impact of marigold SFE on the
mitochondrial oxidative respiration of pancreatic cancer cells.
By means of the Extracellular Flux Bioanalyzer (Seahorse
Bioscience), wemonitored the OCRs after the sequential addition
of different drugs, which regulate the mitochondrial function.
As we have previously described (Mouhid et al., 2018), the
IC50 (dose concentration that inhibits 50% of cell proliferation)
of marigold SFE after 48 h of treatment was 39.8 (± 4.6) µg/ml
for MiaPaca-2 cells. The LC50 (µg/ml) (concentration needed for
50% cell death) after 48 h of treatment was 78.5 (± 1.4) µg/ml.
For this reason, the study of cell bioenergetics (mitochondrial
oxidative phosphorylation and aerobic glycolysis) was performed
after treatment of MiaPaca-2 cells for 48 h with different doses of
marigold SFE, corresponding to ½ × IC50 (¼ × LC50), 1 × IC50
(½ × LC50), and 2 × IC50 (1 × LC50). Non-treated cells were
kept as controls. Importantly, before running the experiments,
the very same number of non-treated cells and pretreated cells
(40,000 cells per well) was plated in an XFe Seahorse plate in
complete media (DMEM, 10% FBS, for 4 h to allow the cells
to attach), without any treatment, in order to compare the cell
bioenergetics only of viable cells. Then, the medium of the cells
was changed to the non-buffered XFe base media supplemented
with 10mM glucose, 2mM glutamine, and 1mM pyruvate, and
cells were incubated for 1 h at 37◦C without CO2.
As it can be observed in Figure 2A (left panel, bioenergetic
profile), MiaPaca-2 pancreatic cancer cells pretreated with
marigold SFE showed a reduced basal respiration rate compared
with control non-treated cells (measurements 1–3) at all the
doses tested. After injection of oligomycin, in order to estimate
the OCR dedicated to ATP production, marigold SFE pretreated
cells displayed reduced levels of ATP compared to control
non-treated cells (measurements 4–6). The maximal respiration
rate (measurements 7–9), after the injection of FCCP, was also
affected in marigold SFE pretreated cells. Finally, rotenone
and antimycin A, inhibitors of complexes I and III of the
electron transport chain, respectively, were injected to shut
down the OCR due to mitochondrial oxidative phosphorylation
(measurements 10–12). These results indicate that marigold SFE
clearly compromises mitochondrial respiration.
More dramatic results were obtained when the same
experiment was performed in a reduced glucose condition
(2.5mM glucose) (Figure 2B).
These results indicate that, even at the lowest dose (20µg/ml)
of treatment, where cell viability is not highly compromised (¼ of
the LC50 dose), marigold SFE compromises the cell bioenergetics
of MiaPaca-2 pancreatic cancer cells.
Marigold Diminishes Aerobic Glycolysis of
Pancreatic Cancer Cells
To analyze the effect of marigold SFE on aerobic glycolysis,
we monitored the ECAR, an indirect readout of the L-lactate
production, after sequential injection of modulators of the
aerobic glycolysis. MiaPaca-2 cells were pretreated for 48 h with
three different doses of marigold SFE corresponding to ½× IC50,
1 × IC50, and 2 × IC50, with IC50 being equal to 39.8 (± 4.6)
µg/ml. Non-treated cells were kept as controls. Then, 20,000
cells were plated per condition (six replicates for control and six
replicates for the different doses of marigold SFE pretreated cells)
in complete media (DMEM, 10% FBS), without treatments, for
4 h to allow the cells to attach. Then, the culture medium was
changed to XFe base media supplemented with 2mM glutamine
without glucose and pyruvate in non-buffered media adjusted
to pH 7.4. Cells were kept for 1 h at 37◦C in an incubator
without CO2.
As it can be observed in Figure 2C (left panel), basal ECAR
of marigold SFE pretreated cells (1 to 3 measurements) was
reduced compared to control non-treated cells. Next, we injected
glucose (10mM final concentration) to monitor the cells’ ability
to upregulate glycolysis when glucose is available. After the
glucose injection, marigold SFE pretreated cells had diminished
levels of ECAR compared to control cells (3–6 measurements),
indicating a reduced capacity for glycolysis Then, oligomycin was
injected to block the ATP production from the mitochondria
and so to determine the maximal glycolytic capacity. Marigold
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FIGURE 2 | Marigold supercritical fluid extraction (SFE) diminishes cell bioenergetics. (A) Mitochondrial respiration analysis by flux analysis of the oxygen consumption
rate (OCR) of MiaPaca-2 cells vs. marigold SFE pretreated cells (½ × IC50, 1 × IC50, 2 × IC50) in complete media (10mM glucose, 2mM glutamine, 1mM pyruvate).
Basal respiration rate, spare respiratory capacity, ATP production, and proton leak are shown. (B) Mitochondrial respiration analysis by flux analysis of the OCR in
MiaPaca-2 non-treated cells vs. marigold SFE pretreated cells for 48 h prior to the experiment, when kept in low glucose (2.5mM glucose, 2mM glutamine, 1mM
(Continued)
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FIGURE 2 | pyruvate). A control of non-treated cells in complete media is shown for comparison with control non-treated cells in conditions of low glucose. (C)
Glycolytic activity of MiaPaca-2 pancreatic cancer cells. Comparison of the glycolytic function of MiaPaca-2 cells vs. marigold SFE pretreated cells (½ × IC50, 1 ×
IC50, 2 × IC50) for 48 h prior to the experiment, in conditions of absence of glucose for 1 h (2mM glutamine). Glycolysis [difference from extracellular acidification rate
(ECAR) value in the presence of glucose and ECAR value in starved cells], glycolytic reserve (difference between ECAR after ATPase inhibition and ECAR after glucose
injection), and glycolytic capacity (sum of glycolysis and glycolytic reserve) are shown. Representative assays of three experiments. Each experiment contains six
replicates per treatment. *P < 0.05.
SFE pretreated cells presented reduced maximal ECAR levels
compared to the control cells (measurements 6–9).
Finally, 2-DG was injected (50mM final concentration)
to shut down aerobic glycolysis and to determine the non-
glycolytic ECAR.
These results indicate that marigold SFE treatment also
compromises aerobic glycolysis.
Different from other systems where there is bioenergetic
plasticity between mitochondrial oxidative respiration and
aerobic glycolysis, herein, marigold SFE diminished both
bioenergetic pathways.
Marigold SFE Leads to AMPK Activation
and Augments the Autophagy Marker
LC3-II
As the two major bioenergetic pathways, mitochondrial
oxidative phosphorylation (Figures 2A,B) and aerobic glycolysis
(Figure 2C), were compromised in marigold SFE-treated
cells compared to control non-treated cells, we wanted to
delve deep into the energetic depletion as a plausible major
cause of pancreatic cancer cell death. Cell death can occur
by different mechanisms, including apoptosis, necrosis, or
autophagy. Nevertheless, ATP depletion is involved in all
processes that mediate cell death. Thus, we quantified the
intracellular ATP content after the treatment with marigold
SFE. MiaPaca-2 cells were pretreated for 48 h with marigold
SFE at ½ × IC50, 1 × IC50, and 2 × IC50. Non-treated
cells were kept as controls. A total of 10,000 cells of each
condition were replated, in complete media without any
treatment, for 6 h before the ATP content quantification. As
shown in Figure 3A, the cellular ATP content was reduced
in marigold SFE pretreated cells in a dose-dependent
manner, being statistically significant at doses of 1 × IC50
and 2× IC50.
The active phosphorylated form of AMPK (P-AMPKα) at
residue Thr172 in the catalytic loop is required to inhibit
essentially all anabolic pathways that promote cell growth. As
it can be observed in Figure 3B, marigold SFE pretreated cells
displayed increased levels of the phosphorylated active form of
AMPK [P-AMPKα (Thr172)].
In response to various cellular stresses, including glucose
starvation and/or ER stress, AMPK can induce autophagy.
To evaluate induction of autophagy, by means of Western
blot, we analyzed the conversion of the soluble form of
LC3 (LC3-I) to the lipidated and autophagosome-associated
form (LC3-II), which is considered one of the hallmarks
of autophagy (Rubinsztein et al., 2007; Klionsky et al.,
2016). As it is shown in Figure 3B, marigold SFE pretreated
cells displayed increased LC3-II levels compared to control
non-treated cells.
Similar results were obtained in Panc-1 pancreatic cancer cells
after treatment with marigold SFE (Figure S1).
Marigold SFE Induces a Dynamic
Autophagy Flux
AMPK activation not only regulates the initiation of autophagy
when the intracellular ATP levels are decreased, but also is
required for the autophagosome maturation and lysosomal
fusion (Jang et al., 2018).
By means of immunofluorescence, the occurrence of LC3-
positive dots was observed after marigold SFE treatments
compared to non-treated cells. Importantly, the addition of the
lysosomal protease inhibitors, E64d and pepstatin A, which block
the last steps of autophagy (Klionsky et al., 2016), augmented the
marigold SFE-induced accumulation of LC3 dots and intensity,
confirming the dynamic autophagy flux induced by marigold
SFE (Figure 4A). Moreover, these results were confirmed by
Western blot, where marigold SFE in the presence of E64d and
pepstatin A displayed increased levels of the lipidated LC3-II
marker (Figure 4B).
Marigold SFE Augments Markers of ER
Stress and AICD
Since autophagy has been implicated in cell survival or cell
death, depending on the intensity, and duration, we wanted to
investigate if the increased autophagic flux could be implicated in
the pancreatic cancer cell death induced by marigold SFE.
A role of ER stress has been described, when energy is
depleted, in the activation of the autophagic flux. Depending on
the duration and intensity, it may end up with AICD.We wanted
to evaluate this possibility by analyzing the effect of marigold SFE
in the expression levels of BIP, which is a marker of ER stress, and
CHOP, which is a marker of AICD.
As shown in Figure 5, marigold SFE increased the expression
levels of BIP and CHOP in a dose-dependent manner.
Importantly, treatment with PBA, which is known to alleviate the
ER stress, also diminished the expression levels of CHOP.
BMP8B Is a Molecular Target of Marigold
SFE
To identify putative molecular targets of marigold SFE,
a comparative gene expression microarray (G2519F-026652
Human Gene Expression v2 4x44K Microarray) was performed
(Link to raw data: https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE124043).
For this, MiaPaca-2 cells were treated with two doses of
marigold SFE (30 and 70µg/ml) for 48 h, to be compared
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FIGURE 3 | Marigold SFE leads to AMPK activation and increased markers of autophagy (LC3-II). (A) Measurement of the intracellular ATP content. Luminescence
units were registered for marigold SFE pretreated cells (½ × IC50, 1 × IC50, and 2 × IC50) and compared to control non-treated cells. (B) Western blot analysis of
P-(Thr172) AMPK and Total AMPK protein levels, and LC3 protein. Cells incubated for 6 h in low glucose (2.5mM) were kept as a positive control of AMPK activation
and LC3 lipidated form (LC3-II). **P < 0.01, ***P < 0.005.
FIGURE 4 | Effect of marigold SFE on induction of autophagy. (A) LC3 immunostaining. Representative images of control and marigold SFE-treated cells (48 h) at two
different doses corresponding to 1 × IC50 and 2 × IC50, in the absence (left panel) or presence of E64d (10µM) and pepstatin A (PA; 10µg/ml) (right panel). Scale
bar: 20µm. (B) Effect of marigold SFE on LC3 lipidation in MiaPaca2 cells pretreated at two different doses corresponding to 1 × IC50 and 2 × IC50 for 48 h and
control non-treated cells, in the presence/absence of E64d (10µM) and PA (10µg/ml).
to control non-treated cells. Genes whose expression was
significantly changed at the two doses (P < 0.05), with a >two-
fold change compared to control cells, are listed in Figure 6A.
By means of quantitative real-time PCR (RT-qPCR) analysis, the
upregulation of BMP8B after marigold SFE treatment in a dose-
dependent manner was validated (30 and 70µg/ml) (Figure 6B,
left panel). We obtained similar results with another pancreatic
cancer cell line, Panc-1, which has been described to be more
aggressive compared to MiaPaCa-2 cells (Yang et al., 2011)
(Figure 6B, right panel).
Upregulation of BMP8B has been demonstrated to diminish
cell invasion and tumor growth in pancreatic xenografts
(Cheng et al., 2014). In line with this, marigold SFE
inhibited cell invasion through Matrigel-coated chambers,
as well as EMT and stemness markers in a dose-dependent
manner (Figure S2).
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FIGURE 5 | Marigold SFE induces the expression of BIP and CHOP. Effect of marigold SFE on the expression levels of BIP and CHOP of MiaPaca-2 cells pretreated
at two different doses corresponding to 1 × IC50 and 2 × IC50 for 48 h, in the presence or absence of PBA. Non-treated cells were kept as controls. Data represent
the mean ± S.E.M of three independent experiments, each one performed in triplicate. Asterisks indicate statistical differences in treated cells in comparison with
control (DMSO); *P < 0.05, **P < 0.01, ***P < 0.005.
FIGURE 6 | BMP8B is a molecular target of marigold SFE. (A) Microarray data of differentially expressed genes after treatment of MiaPaCa-2 pancreatic cancer cell
line with 30 and 70µg/ml marigold SFE for 48 h. Data represent the value of the most significant probe for three independent experiments for each condition. Genes
with a statistically significant difference (P value < 0.05) and more than two-fold absolute change variation compared to control (DMSO) are shown. (B) Validation of
the upregulation of BMP8B after marigold SFE treatment in two pancreatic cancer cell lines, MiaPaca-2 and Panc-1. Non-treated cells were kept as controls. Data
represent the mean ± S.E.M. of three independent experiments, each one performed in triplicate. Asterisks indicate statistical differences in treated cells in
comparison with control (DMSO). **P < 0.05, ****P < 0.001 indicate statistically significant differences refered to the control C.
Silencing BMP8B Counteracts the Effect of
Marigold SFE on Mitochondrial Oxidative
Phosphorylation
Bone morphogenetic proteins (BMPs) have been described to
have an impact on the systemic energy balance by targeting
brown and white adipose tissues. BMP8B central administration
induces thermogenesis and augments the core temperature,
leading to weight loss (Whittle et al., 2012). To demonstrate
the functional link of BMP8B after marigold treatment with
the observed effects on cell bioenergetics and autophagy, we
performed rescue experiments to diminish BMP8B RNAm levels.
For this, MiaPaca-2 pancreatic cancer cells were transfected
with si-RNA pools against the human BMP8B mRNA (siTOOLs
Biotech GmbH). Twenty-four hours later, cells were treated with
two different doses of marigold SFE for 48 h [d1 = 1 × IC50
and d2 = 2 × IC50, with IC50 being 39.8 (±4.6) µg/ml for
MiaPaca2]. Cells transfected with a negative control siPOOLwere
kept as controls.
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FIGURE 7 | Depletion of BMP8B counteracts the effect of marigold SFE on the inhibition of mitochondrial oxidative phosphorylation. (A) Mitochondrial respiration
analysis by flux analysis of the OCR in MiaPaca-2 transfected with si-RNA pools against BMP8B or si-RNA-scramble, in non-treated cells and marigold SFE-treated
(Continued)
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FIGURE 7 | cells (1 × IC50, 2 × IC50). Lower panels: basal respiration rate, spare respiratory capacity, ATP production, and proton leak. (B) Quantitative real-time
PCR (qRT-PCR) validation of the partial inhibition of BMP8B by means of si-RNA pools against BMP8B in MiaPaca-2 cells. (C) Effect of marigold SFE on the
expression levels of BIP and CHOP in MiaPaca-2 cells transfected with si-RNA pools against BMP8B or si-RNA-scramble. (D) Mitochondrial respiration analysis by
flux analysis of the OCR in Panc-1 cells transfected with si-RNA pools against BMP8B or si-RNA-scramble, in non-treated cells and marigold SFE-treated cells (1 ×
IC50, 2 × IC50). (E) qRT-PCR validation of partial inhibition of BMP8B by means of si-RNA pools against BMP8B in Panc-1 cells. (F) Effect of marigold SFE on the
expression levels of BIP and CHOP in Panc-1 cells transfected with si-RNA pools against BMP8B or si-RNA-scramble. *Indicates statistical differences referred to
control non-treated cell transfected with siRNA scramble: *P < 0.01; **P < 0.05, ***P < 0.005, ****P < 0.001. # Indicates statistical differences between siRNA
BMP8B and siRNA scramble transfected cells for each condition: #P < 0.05, ##P < 0.01, ###P < 0.005, ####P < 0.001.
Importantly, silencing BMP8B was able to partially counteract
the effect of marigold SFE on the inhibition of the mitochondrial
oxidative phosphorylation (Figure 7A). RT-qPCR confirmed the
partial downregulation of BMP8B in MiaPaca-2 transfected
cells with si-RNA pools against BMP8B, but not with the si-
RNA scramble (Figure 7B). In addition, we also found that
diminishing BMP8B also correlated with the levels of LC3-II,
which were also diminished in siRNA BMP8B transfected cells
compared to the si-RNA scramble transfected cells (Figure S3).
These results suggest that the energetic depletion is linked to the
activation of autophagy.
To determine if the activation of autophagy could be linked
to the observed effects on cell viability, we analyzed the markers
of ER stress and its downstream mediator of apoptotic cell death
CHOP. As shown in Figure 7C, reducing BMP8B in marigold-
treated cells was able to alleviate, to some extent, ER stress (BIP
marker) and CHOP expression levels.
These results were also validated in Panc-1 pancreatic cancer
cells (Figures 7D–F).
DISCUSSION
There is great concern about the increase in chronic diseases
related to metabolism such as obesity, insulin resistance,
cardiovascular diseases, and cancer. Moreover, current
evidence demonstrates that up to one third of cancer
deaths could be prevented by modifying key risk factors,
with diet and exercise being among the most important
due to their association with obesity (Parkin et al., 2011;
Brown et al., 2018). Although the biology that connects
metabolic dysfunction with cancer development at either
cellular or systemic level is not fully understood, accumulating
evidence suggests that the overall metabolic state of an
individual may contribute to the molecular alterations
during carcinogenesis.
In the context of precision nutrition, nutrient components,
extracts, and bioactive compounds from natural sources
(nutraceuticals) can have an impact on cancer initiation and/or
on cancer progression by regulating gene expression and/or
associated risk factors such as obesity and chronic inflammation.
The reprogramming of energy metabolism is a key event in
tumorigenesis (Hanahan and Weinberg, 2011), and efforts are
oriented to develop therapeutic strategies toward the altered
cancer metabolism and/or associated molecular alterations.
Dysregulated metabolism also has an impact on the oncogenic
pathways of cancer, and diet is a contributing factor to supply
cancer metabolic requirements.
Vegetables and plants are among the most popular sources
to obtain bioactive compounds. Phytochemicals exert numerous
biological activities, such as anti-inflammatory, antihypertensive,
antioxidant, anticarcinogenic, antidiabetic, or antiobesity. Thus,
targeted nutritional interventions may contribute to enhancing
cancer therapy and survival of cancer patients.
The success of such nutritional interventions requires
several steps: (i) in vitro and preclinical demonstration of
the antitumoral effects of selected extracts and/or bioactive
compounds; (ii) the knowledge of their mechanism of action
and molecular targets, which will identify the specific subgroups
of patients that will benefit from them; (iii) the study of
genetic variants associated with the differential responses to the
intervention; and (iv) innovative approaches of new formulations
to improve the in vivo bioavailability. Moreover, additional
factors such as the gut microbiome composition, the immune
system, and the nutritional status will refine the final outcome.
Innovative methodologies are being developed to obtain new
bioactive compounds or extracts, which potentially could target
the altered cancer metabolism. Within the most promising
methods, the green technology of SFE is quite popular nowadays,
with special use in the extraction of compounds with low polarity,
which are soluble in supercritical CO2. This technology can be
assisted by distinct co-solvents such as ethanol, which may also
enhance the yield of extraction.
The antitumoral activities of different extracts obtained from
marigold have been previously evaluated. Thus, extracts obtained
with polar solvents (i.e., hexane, chloroform, ethyl acetate, and
methanol) have been shown to display cytotoxic activity against
breast cancer cell lines (Abutaha et al., 2019), and extracts
obtained by laser have also been evaluated in pancreatic cancer
(Fryer et al., 2011), leukemia, and fibrosarcoma cell lines (Ukiya
et al., 2006), as well as ethyl alcohol extracts inmelanoma (Preethi
et al., 2010). To our knowledge, the antitumoral activities of
supercritical extracts obtained from marigold have not been
previously described.
For this reason, herein, we have investigated the antitumoral
properties and mechanism of action of a supercritical CO2
extract from C. officinalis, commonly known as marigold in the
context of pancreatic cancer, where the 5-year overall survival rate
is<5%.
We have previously described the antitumoral properties of
marigold SFE (Martin et al., 2016; García-Risco et al., 2017) in
pancreatic cancer cell lines (Mouhid et al., 2018). Herein, we
aimed to investigate the impact of marigold SFE on pancreatic
cancer metabolism. By means of the use of the latest technology
in the field of cell bioenergetics, we analyzed the impact of
marigold SFE on mitochondrial oxidative phosphorylation and
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aerobic glycolysis. We functionally demonstrate that marigold
SFE targets cell bioenergetics (Figure 2) and diminishes the
ATP content of pancreatic cancer cells (Figure 3) and increases
the autophagy flux (Figure 4, Figure S1). We also show that
marigold SFE increases the ER stress and markers of AICD.
Importantly, alleviating the marigold SFE-induced ER stress with
PBA diminishes the AICD (Figure 5).
Gene expression microarray analysis allowed for identifying
BMP8B as a validated molecular target of marigold SFE
(Figure 6). BMP8B has been proposed to act as a tumor
suppressor in pancreatic cancer, leading to the inhibition of
invasion and tumor growth of pancreatic cancer xenografts
(Cheng et al., 2014). In accordance with this, marigold SFE
inhibited cell invasion as well as markers of EMT and stemness
(Figure S2).
BMP8B, which is expressed in mature brown adipocytes, has
also been demonstrated to amplify the thermogenic response
in brown adipose tissue influencing the systemic energy
balance. Moreover, BMP8B-deficient mice displayed a reduced
thermogenic response and an impairment in diet- and cold-
induced thermogenesis (Whittle et al., 2012). On the contrary,
BMP8B administration induced thermogenesis and increased the
core temperature, as well as promoted weight loss. Interestingly,
this effect results from the sympathetic activation of brown
adipose tissue, without any change in the feeding behavior (Livak
and Schmittgen, 2001).
Importantly, depleting BMP8B by means of siRNAs
counteracts, at least partially, the effect of marigold SFE on
the LC3-II marker (Figure S3), with improvements on cell
bioenergetics (indirect readout of cell viability recovery)
(Figures 7A,D) and also alleviating ER stress and CHOP
apoptotic markers (Figures 7C,E). These findings suggest
that marigold promotes autophagic cell death via ER stress
in pancreatic cancer cells, although we cannot exclude that
autophagy and apoptosis may occur simultaneously. A
deeper study on autophagy downstream players requires
further investigation.
Further studies for the identification of individual bioactive
constituents in the SFE marigold extract, and their individual
or associated roles in pancreatic cancer metabolism are still
necessary before conducting preclinical trials.
In the field of nutraceuticals, additional challenges are directed
to augment the bioavailability of the bioactive compounds during
the gastrointestinal digestion. Despite their bioactive properties,
the use of phytochemicals in the clinics is still limited, mainly
due to their poor bioavailability, and new formulations are
being develop (Mouhid et al., 2017). The use of bioactive lipids
as delivery systems is a very interesting strategy not only to
increase the bioavailability of phytochemicals but also to exert
additional benefits due to their intrinsic bioactivity (Mouhid
et al., 2017). In this regard, this delivery system has been gone
under patent by the group, and a formulation based on the
use of alkylglycerols as a lipidic vehicle has demonstrated to
synergize with rosemary SFE to exert antitumoral activity in
colon cancer both in vitro and in vivo (PCT/ES2017/070263).
Furthermore, in a recent clinical trial, this formulation based
on the combination of alkylglycerols and rosemary SFE has
demonstrated immunomodulatory and molecular effects with
potential benefits in colorectal cancer (Clinical Trial Registry
number: NCT03492086 http://clinicaltrials.gov/), suggesting that
a similar formulation could be applied to marigold in pancreatic
cancer as the next step.
Additional challenges are oriented to understand how
diet might have an impact on cancer development through
the gut microbiota composition, the metabolites derived
from them, and the immune system. The equilibrium
between inflammation and tolerance in the gut can modulate
precancerous lesions to progress or not into cancer (Arpaia
et al., 2013). The nutritional status of individuals also has an
impact by triggering inflammation and affecting the systemic
energy balance.
FUTURE DIRECTIONS
Herein, it is demonstrated that marigold SFE induces BMP8b
in pancreatic cancer leading to AICD. These results open new
stimulating scenarios for the potential applications of marigold
SFE. BMP8b, which is secreted by brown and beige adipocytes,
has been demonstrated to activate thermogenesis, to enhance
energy dissipation, and to increase the sympathetic innervation
and vascularization of AT (Pellegrinelli et al., 2018). Thus,
induction of BMP8b by marigold SFE could be an interesting
strategy for tackling obesity and for promoting metabolic health.
To further confirm these potential applications, a formulation
of marigold with bioactive lipids will be performed to undergo
clinical validation.
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